ENGN

enGene Therapeutics Inc. · NASDAQ:ENGN

1.45 USD−0.0800 −5.23%

enGene Therapeutics Inc. (NASDAQ:ENGN) last traded at 1.45 USD, down 5.23% on the day. Over the past year the stock is down 79.17%. Its 52-week range is 1.40 to 12.25. It is in the Commercial Services sector (Miscellaneous Commercial Services).

Key statistics

Open1.55

Day range1.45 – 1.55

52-week range1.40 – 12.25

Volume587.19 K

Average volume (10 days)800.93 K

Market cap97.17 M

EPS (TTM)−2.08

Dividend yield0.00%

Beta (1 year)1.24

Revenue (TTM)0

Employees82

Performance

−7.64%1 week

−27.50%1 month

−18.54%3 months

−81.76%6 months

−84.05%Year to date

−79.17%1 year

Technical reading

Strongly bearish

Daily summary of what 11 oscillators and 15 moving averages show. See every indicator

Latest headlines

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update PathMarketBeat · 16 Oct 2026
ENGN: Polidocanol may boost gene expression and cut dwell time; clinical testing is underwayQuartr · 15 Oct 2026
ENGN: Detalimogene’s case rests on tolerability and workflow fit, with surfactant benefits still to be proven clinicallyQuartr · 15 Oct 2026
enGene to Host KOL Webinar on October 15, 2026BusinessWire · 13 Oct 2026
ENGN: Detalimogene achieves strong efficacy and safety in NMIBC, targeting a $20B+ marketQuartr · 15 Sep 2026
ENGN: Detalimogene advances toward 2027 approval with strong efficacy, tolerability, and market fitQuartr · 15 Sep 2026
ENGN: Detalimogene shows strong efficacy and safety, targeting rapid adoption in NMIBC community careQuartr · 14 Sep 2026
enGene Therapeutics Inc. reports results for the quarter ended July 31 - Earnings SummaryReuters · 09 Sep 2026

Market data is delayed as each exchange requires (see data coverage). SuperCharting is charting software and gives no investment advice.